Berberine Suppresses SASP Inflammation via RXRα/PPARγ/NEDD4 Axis

Study Background and Research Question

Chronic inflammation driven by senescent cells is a major contributor to age-related diseases, including atherosclerosis. Senescent cells exhibit the senescence-associated secretory phenotype (SASP), characterized by secretion of pro-inflammatory cytokines, chemokines, and matrix remodeling factors that exacerbate tissue dysfunction and disease progression. Single-cell sequencing of human carotid plaques reveals that aging foam cells—primarily macrophage-derived—are abundant and exhibit robust SASP activity, underscoring their central role in vascular inflammation (see summary).

Berberine (BBR), a plant-derived alkaloid, has shown promise in reducing cellular senescence and associated inflammation in cardiovascular contexts. However, the molecular mechanisms by which berberine modulates SASP in atherosclerosis remained poorly defined. The reference study by Zheng et al. (full reference) addresses this gap, specifically focusing on the RXRα/PPARγ/NEDD4 signaling pathway in macrophage-derived foam cells.

Key Innovation from the Reference Study

The main innovation of this research lies in elucidating a mechanistic link between berberine and suppression of SASP-driven inflammation through the RXRα/PPARγ/NEDD4 axis. The study provides evidence that berberine activates both RXRα and PPARγ, synergistically elevating NEDD4 expression, which in turn promotes the ubiquitination-mediated degradation of the GATA4/p62 complex—a key driver of SASP-associated protein production. This pathway was shown to be essential: when RXRα was knocked down specifically in macrophages, berberine's anti-inflammatory effects were abolished (related article).

Methods and Experimental Design Insights

The researchers combined in vivo and in vitro approaches to dissect the effect of berberine on atherosclerotic inflammation:

• Animal models: ApoE^-/- mice were fed a high-fat diet to induce atherosclerosis, with or without berberine treatment. Some mice received lentiviral-mediated knockdown of RXRα in macrophages to test pathway specificity.
• Histological and biochemical analysis: Plaque morphology and blood lipid profiles were assessed to monitor disease progression and treatment effects.
• Cellular studies: RAW264.7 macrophages and peritoneal macrophage-derived foam cells were used to model SASP in vitro. Berberine's impact on SASP protein production was quantified.
• Smart-seq transcriptomics: Single-cell RNA sequencing enabled pathway interrogation and identification of upregulated NEDD4 following berberine exposure.
• Protein interaction assays: The study assessed GATA4 binding to p62 and downstream ubiquitination events, clarifying the biochemical basis for SASP suppression.

Collectively, these methods provided a robust platform to map the RXRα/PPARγ/NEDD4 axis and its role in modulating SASP-related inflammation.

Core Findings and Why They Matter

1. Activation of RXRα/PPARγ/NEDD4 by Berberine: Berberine treatment led to increased activity of both RXRα and PPARγ in macrophage-derived foam cells. This, in turn, upregulated NEDD4 transcription, as confirmed by Smart-seq transcriptomics.

2. Ubiquitin-Mediated Degradation of GATA4/p62: Elevated NEDD4 promoted ubiquitination and proteasomal degradation of the GATA4/p62 complex. Since GATA4 is a known regulator of SASP gene expression, its degradation resulted in reduced secretion of SASP-associated inflammatory proteins.

3. SASP and Plaque Stabilization: In vivo, berberine reduced the abundance of senescent foam cells and attenuated pro-inflammatory cytokine production within atherosclerotic plaques, leading to improved plaque morphology and decreased disease severity.

4. Pathway Specificity: Importantly, when RXRα was knocked down in plaque macrophages, berberine no longer suppressed SASP or improved plaque features. This underscores the essential role of the RXRα/PPARγ/NEDD4 axis in mediating berberine's anti-inflammatory effects (see also).

Overall, these findings clarify a previously uncharacterized anti-inflammatory mechanism for berberine and suggest that targeting the RXRα/PPARγ/NEDD4 axis could be a potent strategy to suppress SASP-driven vascular inflammation.

Comparison with Existing Internal Articles

Several recent articles have explored the modulation of the RXRα/PPARγ/NEDD4 pathway in cellular aging and inflammation. For example, a feature on T0070907 highlights how a selective PPARγ antagonist can be used to dissect this signaling axis. T0070907 enables researchers to block PPARγ function with high specificity (IC₅₀ ~1 nM), making it a valuable tool for distinguishing PPARγ-dependent from independent effects in SASP and adipogenesis inhibition assays.

Furthermore, another mechanistic overview details how PPARγ antagonists such as T0070907 modulate not only adipogenic differentiation but also cell cycle G2/M arrest, which is relevant for studies on cellular senescence and proliferation in disease models. These internal resources complement the reference study by providing practical details on how to experimentally interrogate the RXRα/PPARγ/NEDD4 axis and its downstream effects.

Limitations and Transferability

Although the reference study provides compelling evidence for the RXRα/PPARγ/NEDD4 axis in suppressing SASP-driven inflammation, several limitations warrant consideration:

• Model specificity: Most data are derived from mouse models and in vitro macrophage studies. While single-cell sequencing supports the relevance of these pathways in human plaques, direct validation in human tissue or clinical trials is needed for translational certainty.
• Pathway complexity: The interplay between RXRα, PPARγ, and NEDD4 may involve additional co-factors or regulatory mechanisms not fully explored in this study.
• Drug specificity: Berberine is a pleiotropic molecule; some effects may extend beyond the RXRα/PPARγ/NEDD4 pathway, complicating data interpretation in complex systems.

Transferability to other models of chronic inflammation or aging should be approached cautiously, with further validation required in diverse cellular and organismal contexts.

Protocol Parameters

• Berberine dosing in vivo: ApoE^-/- mice were administered berberine orally; dosing regimens in the reference study can be adapted for preclinical atherosclerosis models, with careful monitoring of metabolic variables and plaque progression.
• PPARγ antagonist application: For mechanistic dissection, selective PPARγ antagonists such as T0070907 can be applied to cultured macrophages or foam cells at nanomolar concentrations (e.g., 1–10 nM) to block PPARγ transactivation and assess pathway dependence.
• Knockdown strategies: Lentiviral shRNA targeting RXRα in macrophages provides pathway specificity and can be combined with pharmacological inhibitors in both in vitro and in vivo models.
• SASP readouts: Quantify SASP-associated cytokines (e.g., IL-6, TNF-α) and transcriptional regulators (GATA4, p62) by ELISA, qPCR, or immunoblotting before and after treatment interventions.

Research Support Resources

To experimentally dissect the RXRα/PPARγ/NEDD4 pathway or validate berberine targets, researchers can utilize selective PPARγ antagonists such as T0070907 (SKU A4301) from APExBIO. T0070907 offers high affinity (IC₅₀ 1 nM) and specificity for PPARγ, enabling precise modulation of PPARγ signaling in cell culture or biochemical assays. For protocols requiring inhibition of adipogenesis, modulation of PPARγ/RXRα heterodimer activity, or investigation of cell cycle G2/M arrest, T0070907 provides a robust tool to complement mechanistic studies on SASP and vascular inflammation.